Skip to content
CancerIndex

Publication

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Authors not recorded

BMC Cancer2016PMID 27485109PMC4970247stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (5)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
27485109
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
ABL1 BCR::ABL F317L1
DasatinibChronic Myeloid Leukemia, BCR-ABL1 PositiveALIASPredictiveCSupports Resistance—rejected
EID4389

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic
ABL1 F317V1
DasatinibChronic Myeloid Leukemia, BCR-ABL1 PositiveALIASPredictiveCSupports Resistance—rejected
EID4536

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic
ABL1 F317L + ABL1 F317V + ABL1 Fusion1
DasatinibChronic Myeloid Leukemia, BCR-ABL1 PositiveALIASPredictiveBSupports Resistance2accepted
EID4386

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, 26 patients relapsed on dasatinib. Of these, there were 10 patients with the F317L or F317V mutation in the ABL1 portion of the B… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic
ABL1 T315I + ABL1 Fusion1
DasatinibChronic Myeloid Leukemia, BCR-ABL1 PositiveALIASPredictiveBSupports Resistance2accepted
EID4368

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the T315I mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=13) were associated with acquired resistant t… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic
ABL1 V299L + ABL1 Fusion1
DasatinibChronic Myeloid Leukemia, BCR-ABL1 PositiveALIASPredictiveCSupports Resistance3accepted
EID4541

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the V299L mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=3) were associated with acquired resistant to… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

civic